Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Statistical significance for genomewide studies
2003 Standout
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
2003
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Identification of the haematopoietic stem cell niche and control of the niche size
2003 StandoutNature
The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis
2007
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
2008
Enrichment analysis in high-throughput genomics—accounting for dependency in the NULL
2006
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
mTOR Signaling in Growth Control and Disease
2012 Standout
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
2005
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
2007
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Multiple Myeloma
2004
Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
1997
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma
2002
Multiple myeloma
2000 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
2009
Neurologic Complications of Plasma Cell Disorders
2004
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
2002
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
2008 Standout
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
2003
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Wnt/β-Catenin Signaling and Disease
2012 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
2007
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation
2007
Genetic events in the pathogenesis of multiple myeloma
2007
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
2003
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006
Prevention of Venous Thromboembolism
2004 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Pathogenesis and treatment of renal failure in multiple myeloma
2008
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Thalidomide
2004
Prevention of Venous Thromboembolism
2008 Standout
Multiple myeloma: evolving genetic events and host interactions
2002
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
2004
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
2006
Mechanisms of Bone Metastasis
2004 Standout
The molecular characterization and clinical management of multiple myeloma in the post-genome era
2009
Respiratory syncytial virus infection following hematopoietic stem cell transplantation
2002
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Wnt signalling in stem cells and cancer
2005 StandoutNature
Obesity is associated with macrophage accumulation in adipose tissue
2003 Standout
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
2006
Toward Regenerative Medicine
2001
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Chemotherapy-induced thrombosis
2006
Tumor Angiogenesis
2008 Standout
The cancer genome
2009 StandoutNature
The thalidomide saga
2007
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.
2001
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements
2007 StandoutNobel
Recent major improvement in long-term survival of younger patients with multiple myeloma
2007
Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
2010
Acute Myeloid Leukemia
2015 Standout
Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
2007 StandoutNobel
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
2010
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
2004
Thalidomide and thrombosis
2007
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Induction Of Kidney Allograft Tolerance After Transient Lymphohematopoietic Chimerism In Patients With Multiple Myeloma And End-Stage Renal Disease1
2002
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial
1999
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
2007
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
2003
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
2011 StandoutScience
From patterns to pathways: gene expression data analysis comes of age
2002
The molecular classification of multiple myeloma
2006
A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
2003
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
2006 StandoutNobel
Genetics and Cytogenetics of Multiple Myeloma
2004
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Cancer Genome Landscapes
2013 StandoutScience
How I treat multiple myeloma in younger patients
2009
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
2005
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
2004
Multiple Myeloma
2011 Standout
Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection
2007
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
2009
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
2005 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
2000
Thromboembolism in Hospitalized Neutropenic Cancer Patients
2006
Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver
2007
Works of Athanasios Fassas being referenced
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
2007
Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
2002
Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen
2003
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients
2006
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
2002
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
2000
Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
2002
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
2004
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
1998
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
2003
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients
2006
Thalidomide in the management of multiple myeloma
2001
Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival
2003
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
Anti‐myeloma activity of pamidronate in vivo
1998
Fatal Disseminated Adenoviral Infection Associated with Thrombotic Thrombocytopenic Purpura after Allogeneic Bone Marrow Transplantation
2001
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
1998
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
2003
Transplantation as salvage therapy for high-risk patients with myeloma in relapse
2002
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
2001
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
2002
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
2004
Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features
2003
Cerebral Demyelination with 5-Fluorouracil and Levamisole
1994
Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants
2002
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy
1999
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
2003
DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma
2003
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
1999
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management
2003
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).
2004
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
2001
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
2002
Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma
1998
Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).
2004
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
2001
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
1999
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
2005